Table 1 Demographic and clinical characteristics of patients with a history of uveitis
Characteristics | COVID-19 infected patients | COVID-19 uninfected patients | P Value |
|---|---|---|---|
(n = 288, eyes = 482) | (n = 61, eyes = 102) | ||
Age (years) (M-IQR) | 31.0 (14.0–46.0) | 31.0 (15.0–55.0) | 0.374 |
Gender (Male/female) (n, %) | 130 (45.1)/158 (54.9) | 35 (57.4)/26 (42.6) | 0.062 |
Course of disease (years) (M-IQR) | 2.50 (1.17–4.90) | 3.4 (1.54-6.00) | 0.033 |
BCVAa (logMAR, M-IQR) | 0.00 (0.00-0.22) | 0.10 (0.00-0.30) | 0.100 |
The anterior chamber cell grade recorded as 0b (eyes, %) | 398 (82.6) | 82 (80.4) | 0.601 |
Infective uveitis (n, %) | 9 (3.1) | 4 (6.6) | 0.361 |
Anatomical classification (n, %) | |||
Anterior uveitis | 30 (10.4) | 11 (18.0) | 0.093 |
Intermediate, posterior or panuveitis | 258 (89.6) | 50 (82.0) | |
Uveitis-related systemic diseases (n, %) | |||
Vogt-Koyanagi-Harada disease | 47 (16.3) | 4 (6.6) | 0.05 |
Behcet’s disease | 26 (9.0) | 5 (8.2) | 0.836 |
Ankylosing Spondylitis | 19 (6.6) | 2 (3.3) | 0.488 |
Other diseasesc | 16 (5.6) | 5 (8.2) | 0.623 |